Glucagon-like peptide 1 receptor (GLP-1R) agonists have been detailed in a Fortvita Biologics Inc. patent. They are reported to be useful for the treatment of arthritis, coronary heart diseases, dementia, diabetes, hyperlipidemia, inflammatory bowel diseases, obesity and substance abuse and dependence.
Phosphatidylinositol 3-kinases (PI3Ks) are a family of enzymes that catalyze the phosphorylation of phosphatidylinositol at the D-3 position of the inositol ring, serving critical functions in cellular signaling pathways. Among them, the isoform PI3K class II γ (PI3KC2γ), which is predominantly expressed in the liver, regulates hepatic glycogen synthesis and thus plays a critical role in glucose homeostasis.
Mira Pharmaceuticals Inc. has reported new in vitro preclinical data supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by Skny Pharmaceuticals Inc.
Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.
In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in this inflammatory disease. This finding could be explored for the development of drugs that protect neurons from damage in MS and other neurodegenerative disorders.
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.
Researchers from the Universitat de Barcelona and Oregon Health & Science University have developed a novel gene silencing technique using polypurine reverse Hoogsteen hairpins (PPRH) to target and inhibit the expression of PCSK9.
Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA).
Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 1 diabetes, atherosclerosis, type 2 diabetes, obesity, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), hypertension, diabetic complications and coronary heart disease among others.
Ascletis Pharma (China) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), diabetes, obesity, metabolic syndrome and more.
RSS
